Discussion
Gliomas are tumours of nervous tissue origin, composed of cells closely resembling astrocytes, oligodendrocytes or ependymal cells, the respective tumours being known as astrocytomas, oligodendrogliomas and ependymomas. Anaplastic forms also occur which contain pleomorphic, less well differentiated cell types.
Extramedullary (or heterotopic) gliomas occur outside the brain or spinal cord. They are most commonly ependymomas. Cooper et al. 2 have previously reported a series of15 extramedullary gliomas which occurred along the spinal axis, but without any apparent attachment thereto, and which had not arisen by seeding from a primary intramedullary glial or intracerebral neoplasm. Characteristic features of extramedullary gliomas are: (1) lack of attachment to the central nervous system and absence of signs of a primary neoplastic process within the brain or spinal cord; (2) the encapsulated appearance of the tumour; (3) location of the tumour along the neuraxis and predominantly in the lumbosacral region", The patient described in this report exhibits all of these features.
Often extramedullary gliomas are associated with congenital abnormalities such as myelomeningocele, spina bifida, club foot, undescended testes and lumbosacral spondyliolistheais", Thus, having identified one of these rare tumours in a patient, it is important to look for any associated congenital abnormalities as well as performing a careful neurological assessment.
The mechanism of formation of extramedullary gliomas is considered to be a 'pinching off of glial tissue from the neural tube, in the same way that dermoid and epidermoid tumours arise from aberrant cutaneous tissue which is caught in the closure ofthe neural tube, thus enabling cutaneous tissue to come to rest in the intramedullary portion of the neuraxis. The majority of such heterotopic glial and dermoid tumours occur in this lumbosacral region, and Humphrey! concluded that this was because it is at the caudal end of the embryo, where disparities in the developmental rates of related structures most often lead to abnormalities.
Tumours of neural origin should be considered when no obvious cause of perianal discomfort or pain is found in the sacrococcygeal region. Adult idiopathic thrombocytopenic purpura (ITP) is a disorder which rarely remits spontaneously and may be associated with considerable morbidity and a mortality rate of 5% I • The management of refractory cases with sufficiently severe thrombocytopenia to cause bleeding often poses a major clinical problem, as transfused platelets rarely reduce the bleeding tendency or result in a rise in the circulating platelet count. We report the successful use of high-dose intravenous immunoglobulin in increasing the platelet count in three cases of severe idiopathic thrombocytopenic purpura, in whom treatment with corticosteroids was unsuccessful or contraindicated.
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Case reports
Case 1: A 65-year-old woman presented to her general practitioner with a three-week history of bruising of the lower limbs. For five years she had been treated with Aldactide 50 (hydroflumethiazide 50 mg and spironolactone 50 mg) two tablets daily for mild hypertension. She had a perforated duodenal ulcer one year previously and was on a maintenance dose of cimetidine 400 mg at night. Physical examination revealed scattered petechiae on the lower limbs and an aortic aneurysm was palpable in the epigastrium.
The platelet count was reduced at 30 x 10 9 /1, and this was thought to be drug-induced thrombocytopenia. All treatment was withdrawn but three months later her platelet count was unchanged and she was referred for further investigation of thrombocytopenia and abdominal aneurysm. Haematological investigation showed a haemoglobin concentration of 12.5 gldl, white cell count of 5.4 x 10 9 11 and platelet count 34 x 10 9 11. Serum B I 2 and folate and red cell folate were normal. Rheumatoid factor, antinuclear factor and viral screen were negative. Platelet-associated IgG (PAlgG) and IgM (PAlgM) levels were elevated. Sternal bone marrow aspirate showed an increased number of megakaryocytes. Abdominal ultrasound revealed a greatly enlarged aortic aneurysm extending from the coeliac axis to the iliac vessels.
Urgent surgical repair of the aneurysm was required and a normal platelet count was considered necessary prior to operation. High-dose steroids were contraindicated in view of her history of peptic ulceration. High-dose immunoglobulin (1.0 g/kg/day; total dose 62 g/day) was infused intravenously over two days. Within 24 hours of infusion the platelet count rose to a normal level. Splenectomy and repair 
Discussion
In adults, ITP is often a chronic disease and spontaneous remissions are rare. The acute treatment ofITP in the adult is usually straightforward. About 7o-B5% of patients achieve remission following treatment with corticosteroids combined in many cases with splenectomy. There are a number of different second-line treatment regimens for those 15-30% of patients who do not obtain a satisfactory response. These include vinca alkaloids, immunosuppressive therapy, vincristine 'loaded' platelets, danazol and colchicine. Although all have been shown to be of value in the treatment of refractory ITP, there are considerable side effects associated with each form of therapy. In addition, there are no satisfactory controlled trials of the various regimens and often no firm recommendations can be made.
Recently there have been reports describing the effectiveness of intravenous immunoglobulin in elevating the platelet count in ITP. This effect has been seen in adults--s, children" and in acute as well as chronic ITP. The mechanism of action appears to be transient reticuloendothelial Fc receptor blockade s. When administered at a dose of 0.4 g/kg body weight/day intravenously for 5 days or 1 g/kg body weight/day for 2 days, about 75-80% of adults with ITP will respond with a significant increase in platelet count, usually within 48 hours of commencing infusion. Platelet function has been shown to be normal following intravenous immunoglobulins. Whilst prolonged remissions have been documented, the benefit in chronic ITP is frequently transient, usually lasting for about three weeks3.6. The response is reproducible and can be repeated on several occasions without loss of effect. The transient nature of the responses in the majority of adults with ITP limits the usefulness of intravenous immunoglobulin for long-term therapy. It is, however, useful in the emergency situation or in the preparation for surgery of patients with refractory ITP. In addition, as our cases illustrate, it can be used in patients in whom steroids are contraindicated or in those patients who fail to respond to steroids.
fifth day of infusion the platelet count was 374 x 10 9 /1. Splenectomy was performed and during the postoperative period the platelet count rose to 1220x 10 9/1; it subsequently returned to normal (Figure 1) . Case 2: An 84-year-old woman was admitted with a three-week history of tiredness and bruising affecting the lower limbs. A diagnosis of autoimmune haemolytic anaemia and thrombocytopenia had been made ten years previously and successfully treated with prednisolone. She subsequently suffered three relapses ofhaemolysis and thrombocytopenia and on each occasion a complete remission was achieved with high-dose steroids (60mg/day). On admission she looked pale, jaundiced and there were scattered petechiae and bruises on the lower limbs; the spleen was palpable 4 em below the left costal margin. Investigations showed a haemoglobin concentration of 8.5 g/dl, white cell count of 16.5 x 10 9/1 (85% neutrophils), platelets 8 x 10 9/1 and 22% reticulocytes. The peripheral blood film showed spherocytosis, polychromasia and confirmed the reduced platelet count. Haptoglobin concentration was less than 0.15 g/dl (normal 0.26-5.0 g/dl). A direct antiglobulin test was strongly positive with an IgG and C 3d coating. PAIgG and PAIgM levels were elevated.
These findings confirmed a relapse of autoimmune haemolytic anaemia and thrombocytopenia. Prednisolone 60 mg daily was started and within seven days the haemoglobin concentration had risen to 11.5gjdl and platelet count to 165x 10 9/1, with a reduction in reticulocytes to 7%. Over the next week the prednisolone was reduced to 30 mg/day; after three days at this reduced dose the platelet count dropped to 20 x 10 9/1, with new bruises on the lower limbs. Prednisolone was increased to 60 mg daily and azathioprine 200mg/day started, but after seven days the platelet count was less than 5 x 10 9/1 with extensive bruising on lower limbs and back, and recurrent epistaxis. Intravenous high-dose immunoglobulin (1 g/kg/day; total dose 55 g/day) was given over 2 days. Within 24 hours the platelet count had increased to 65 x 10 9/1 and after 72 hours was normal. She was discharged and the prednisolone and azathioprine were stopped within five weeks. The haemoglobin and platelet counts had remained normal during this period (Figure 1 ).
Case 3: A 16·year-old student developed a rash affecting the lower limbs and trunk over a period of three days. He was not receiving any drug treatment and there was no past or family history of bleeding problems. Physical examination revealed a widespread purpuric rash affecting lower, upper limbs and trunk.
Investigations showed haemoglobin concentration 12.7 g/dl, white cell count 5.9 x 10 9/1, and platelets 5 x 10 9 /1. Viral screen, rheumatoid factor and antinuclear factor were negative. PAIgG and PAIgM levels were elevated. Sternal bone marrow examination showed increased megakaryocytes.
Prednisolone 50 mg daily (1 mg/kg/day) was started and within seven days the platelet count had risen to 117x 10 9 /1. Over the next three days the platelet count dropped to 29 x 10 9 /1. The dose of prednisolone was increased to 60 mg daily and in spite of this the platelet count dropped to 5 x 10 9/1 over the next week. High-dose immunoglobulin 0.4 g/kg/day (18 g/day) was infused intravenously for five days. On the of the extensive abdominal aneurysm were performed without excessive bleeding. The postoperative period was uncomplicated and six months later the patient remained in partial remission (Figure 1) .
Intravenous immunoglobulin concentrates are remarkably non-toxic and few significant adverse reactions have been reported, the most frequent side effect being mild headache which occurs in approximately 20% of'patients", There are many forms of intravenous immunoglobulin preparations currently available for use. Sandoglobulinw (immune globulin IV), prepared by the Swiss Red Cross, has been used in the majority of studies but other preparations have also been shown to be effective 7 • The intravenous immunoglobulin used in our patients was manufactured by the Protein Fractionation Centre ofthe Scottish National Blood Transfusion Centre and the safety of this product, which was issued on a named-patient basis, has recently been reported".
Intravenous immunoglobulin is a very useful treatment in chronic ITP of adults and its use should be considreed in cases refractory to conventional treatment and in whom a rapid increase in platelet count is required.
